Indeed, only 21% of HR+/HER2− patients in our cohort received systemic chemotherapy due to expected insufficient response26, as compared to 68% and 56%, in HER2 + and HR−/HER2− breast cancer, respectively (Table 1). This evidence concerns the gene ERBB2 and breast cancer.